Intranasal administration of ketamine to treat depression
AssigneesIcahn School of Medicine at Mount Sinai, Yale University, National Institute of Health
InventorsDennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, Jr., John H. Krystal
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Claims18
A method of treating depression, comprising intranasally administering to a patient who suffers from said depression and who has not responded to at least two adequate antidepressant treatments a composition comprising ketamine at a dosage sufficient to alleviate symptoms of said depression, wherein the adequate antidepressant treatments are selected from the group consisting of atypical antipsychotics, benzodiazepines, bupropion, electroconvulsive therapy, lamotrigine, lithium, monoamine oxidase inhibitors, selective norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, valproic acid, nefazodone, trazodone, and pramipexole.
Dependencies are inferred from the claim text.